Literature DB >> 24163054

A novel hollow and perforated flexible wire allows the safe and effective local application of thrombolytic therapy in a mouse model of deep vein thrombosis.

Thilo Witsch1, Maximilian Mauler, Nadine Herr, Daniela Stallmann, Christoph Bode, Christoph Hehrlein, Daniel Duerschmied.   

Abstract

We tested the feasibility of local thrombolytic therapy via a novel hollow flexible and perforated wire in a mouse model of deep vein thrombosis. Inferior vena cava (IVC) thrombosis was induced by vessel wall exposure to ferric chloride after laparotomy in anesthetized C57Bl/6 mice. Thrombus formation was visualized by intravital microscopy of rhodamine-labeled platelets and leukocytes. A nitinol hypotube coronary wire with perforated tip was inserted via a 0.8 × 40 mm canula into the IVC lumen distal to the site of ferric chloride exposure. Either tissue plasminogen activator (tPA, alteplase) or saline (control) was administered via the platinum wire distal to the thrombus, avoiding mechanical fragmentation. Thrombus size was assessed by immunohistochemistry (platelet CD41 staining). Intravital microscopy of the IVC demonstrated platelet-containing thrombus growth starting 1 min after ferric chloride exposure. Alteplase administration resulted in significant thrombus size reduction within 10-20 min observed by intravital microscopy and confirmed by histological assessment of IVC cross-sections. Saline-treated mice (n = 4) demonstrated near total IVC occlusion with thrombotic material (84 ± 8% of cross-sectional area in serial sections), whereas alteplase-treated mice showed a dose-dependent decrease of thrombotic area [56 ± 5% with 1.5, 39 ± 4 % with 15 and 21 ± 6% with 150 mg/kg, respectively (n = 4)]. We demonstrate that a flexible hollow and perforated wire enables the successful application of thrombolytic therapy to IVC thrombi in mice without vessel wall perforation. Flexible wire-based thrombolytic therapy appears to be a safe and reliable method for thrombus dissolution even in fragile small veins and may become a promising strategy for targeted therapy of small vessel thrombosis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24163054     DOI: 10.1007/s11239-013-1013-x

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  12 in total

1.  Deep venous thrombosis and pulmonary embolism: prediction, prevention and treatment.

Authors:  W W COON; P W WILLIS
Journal:  Am J Cardiol       Date:  1959-11       Impact factor: 2.778

2.  Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Gordon H Guyatt; Elie A Akl; Mark Crowther; David D Gutterman; Holger J Schuünemann
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

3.  A comparison of reteplase with alteplase for acute myocardial infarction.

Authors: 
Journal:  N Engl J Med       Date:  1997-10-16       Impact factor: 91.245

Review 4.  Catheter-directed thrombolysis in the treatment of iliofemoral venous thrombosis. A review.

Authors:  R Broholm; L Panduro Jensen; N Baekgaard
Journal:  Int Angiol       Date:  2010-08       Impact factor: 2.789

5.  Local thrombolysis for severe cerebral venous sinus thrombosis.

Authors:  X-b Guo; S Guan; Y Fan; L-j Song
Journal:  AJNR Am J Neuroradiol       Date:  2012-03-01       Impact factor: 3.825

Review 6.  Critical review of mouse models of venous thrombosis.

Authors:  Jose A Diaz; Andrea T Obi; Daniel D Myers; Shirley K Wrobleski; Peter K Henke; Nigel Mackman; Thomas W Wakefield
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-03       Impact factor: 8.311

7.  Thrombolysis for experimental deep venous thrombosis maintains valvular competence and vasoreactivity.

Authors:  J M Rhodes; J S Cho; P Gloviczki; G Mozes; R Rolle; V M Miller
Journal:  J Vasc Surg       Date:  2000-06       Impact factor: 4.268

8.  Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial.

Authors:  Tone Enden; Ylva Haig; Nils-Einar Kløw; Carl-Erik Slagsvold; Leiv Sandvik; Waleed Ghanima; Geir Hafsahl; Pål Andre Holme; Lars Olaf Holmen; Anne Mette Njaastad; Gunnar Sandbæk; Per Morten Sandset
Journal:  Lancet       Date:  2011-12-13       Impact factor: 79.321

9.  Contrast ultrasound for the quantification of deep vein thrombosis in living mice: effects of enoxaparin and P2Y12 receptor inhibition.

Authors:  F Guenther; N Herr; M Mauler; T Witsch; F Roming; L Hein; J-M Boeynaems; B Robaye; M Idzko; C Bode; C Von Zur Muhlen; D Duerschmied
Journal:  J Thromb Haemost       Date:  2013-06       Impact factor: 5.824

10.  Inhibition of 12/15-lipoxygenase as therapeutic strategy to treat stroke.

Authors:  Kazim Yigitkanli; Anton Pekcec; Hulya Karatas; Stefanie Pallast; Emiri Mandeville; Netra Joshi; Natalya Smirnova; Irina Gazaryan; Rajiv R Ratan; Joseph L Witztum; Joan Montaner; Theodore R Holman; Eng H Lo; Klaus van Leyen
Journal:  Ann Neurol       Date:  2012-11-28       Impact factor: 10.422

View more
  1 in total

1.  Stenosis of the Inferior Vena Cava: A Murine Model of Deep Vein Thrombosis.

Authors:  Holly Payne; Alexander Brill
Journal:  J Vis Exp       Date:  2017-12-22       Impact factor: 1.355

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.